Vanderbilt University Purchases Shares of 14,730 Progyny, Inc. (NASDAQ:PGNY)

Vanderbilt University acquired a new stake in Progyny, Inc. (NASDAQ:PGNY - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 14,730 shares of the company's stock, valued at approximately $254,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Pacer Advisors Inc. raised its position in Progyny by 47.5% during the fourth quarter. Pacer Advisors Inc. now owns 3,676,200 shares of the company's stock valued at $63,414,000 after purchasing an additional 1,183,558 shares in the last quarter. State Street Corp increased its position in Progyny by 4.5% in the 3rd quarter. State Street Corp now owns 3,113,654 shares of the company's stock valued at $52,185,000 after acquiring an additional 134,861 shares during the period. International Assets Investment Management LLC increased its holdings in Progyny by 1,576.0% in the third quarter. International Assets Investment Management LLC now owns 2,565,118 shares of the company's stock valued at $42,991,000 after purchasing an additional 2,412,068 shares during the period. Invenomic Capital Management LP bought a new stake in Progyny in the third quarter valued at approximately $29,509,000. Finally, Fort Washington Investment Advisors Inc. OH raised its holdings in Progyny by 90.1% during the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company's stock worth $25,319,000 after purchasing an additional 695,740 shares during the last quarter. 94.93% of the stock is owned by institutional investors.

Progyny Price Performance

Shares of PGNY stock traded up $0.09 during trading hours on Friday, reaching $21.92. 1,557,297 shares of the company traded hands, compared to its average volume of 1,883,574. The company has a market cap of $1.87 billion, a P/E ratio of 37.79, a P/E/G ratio of 2.18 and a beta of 1.34. The firm has a 50-day moving average price of $18.34 and a 200 day moving average price of $18.96. Progyny, Inc. has a 12-month low of $13.39 and a 12-month high of $42.08.

Progyny (NASDAQ:PGNY - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported $0.11 EPS for the quarter, missing analysts' consensus estimates of $0.37 by ($0.26). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The firm had revenue of $286.63 million for the quarter, compared to the consensus estimate of $296.85 million. During the same quarter in the prior year, the company posted $0.16 earnings per share. The firm's revenue was up 2.0% compared to the same quarter last year. Sell-side analysts predict that Progyny, Inc. will post 0.6 EPS for the current year.

Insider Buying and Selling at Progyny

In other news, Chairman David J. Schlanger acquired 150,000 shares of Progyny stock in a transaction on Thursday, December 26th. The shares were bought at an average cost of $14.68 per share, for a total transaction of $2,202,000.00. Following the acquisition, the chairman now directly owns 228,269 shares of the company's stock, valued at $3,350,988.92. This trade represents a 191.65 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Peter Anevski purchased 209,500 shares of Progyny stock in a transaction dated Monday, December 23rd. The stock was acquired at an average price of $14.48 per share, with a total value of $3,033,560.00. Following the acquisition, the chief executive officer now owns 441,463 shares in the company, valued at approximately $6,392,384.24. This represents a 90.32 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 12.30% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on PGNY. Bank of America dropped their target price on shares of Progyny from $22.00 to $21.00 and set a "buy" rating on the stock in a research report on Wednesday, November 13th. Barclays decreased their price target on Progyny from $30.00 to $17.00 and set an "overweight" rating for the company in a report on Thursday, November 14th. JPMorgan Chase & Co. lifted their target price on shares of Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 28th. Canaccord Genuity Group reduced their price target on shares of Progyny from $18.00 to $17.00 and set a "hold" rating for the company in a research report on Wednesday, November 13th. Finally, Truist Financial reiterated a "hold" rating and set a $19.00 target price (down previously from $26.00) on shares of Progyny in a research report on Wednesday, November 13th. Nine investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Progyny has an average rating of "Hold" and an average target price of $25.50.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.